Logo
x

Search

Subscribe Now

Nasopharyngeal Carcinoma

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

  • November 2, 2021
Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma

Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma

  • August 13, 2021
Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

  • September 30, 2020
Junshi's Toripalimab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma

Junshi's Toripalimab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma

  • September 10, 2020
Junshi Biosciences Reports MAA Submission of Toripalimab to the MHRA for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

    Junshi Biosciences Reports MAA Submission of Toripalimab to the MHRA for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Car...

    • November 25, 2022
    Junshi Reports MAA Submission of Toripalimab to the EMA for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

      Junshi Reports MAA Submission of Toripalimab to the EMA for Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma

      • November 15, 2022
      Junshi and Coherus Present Results of Toripalimab in P-III (JUPITER-02) Study as 1L Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at AACR 2022

        Junshi and Coherus Present Results of Toripalimab in P-III (JUPITER-02) Study as 1L Treatment of Recurrent or Metastatic Nasophary...

        • April 11, 2022
        Junshi’s Toripalimab Receives the NMPA’s Approval as 1L Treatment for Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

          Junshi’s Toripalimab Receives the NMPA’s Approval as 1L Treatment for Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

          • November 30, 2021
          Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

            Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

            • November 2, 2021
            Junshi and Coherus

              Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma

              • August 13, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.